Mucinous cystadenocarcinoma of the pancreas - outcome following different modes of treatment
(2011) In Annals of Gastroenterology 24(3). p.213-217- Abstract
BACKGROUND: Mucinous cystadenocarcinomas (MCAC) of the pancreas are rare tumors. When localized to the pancreas alone, surgical resection is mostly associated with a favorable prognosis. The potential value of palliative treatment with chemotherapy for irresectable disease is scarcely described though. The aim of this study was to describe a single-center series of patients with MCAC of the pancreas focusing on the outcome following different treatment strategies.
METHODS: 15 patients, 10 females and 5 males, with histologically or cytologically verified MCAC, were divided into three groups: surgical resection (n=7), chemotherapy (n=5) and no treatment (n=3).
RESULTS: There was no obvious difference in gender distribution... (More)
BACKGROUND: Mucinous cystadenocarcinomas (MCAC) of the pancreas are rare tumors. When localized to the pancreas alone, surgical resection is mostly associated with a favorable prognosis. The potential value of palliative treatment with chemotherapy for irresectable disease is scarcely described though. The aim of this study was to describe a single-center series of patients with MCAC of the pancreas focusing on the outcome following different treatment strategies.
METHODS: 15 patients, 10 females and 5 males, with histologically or cytologically verified MCAC, were divided into three groups: surgical resection (n=7), chemotherapy (n=5) and no treatment (n=3).
RESULTS: There was no obvious difference in gender distribution between the subgroups. A tendency towards higher age was seen in the group without treatment, as was a larger tumor size as compared to the chemotherapy group. Patients were administered chemotherapy and the group without treatment seemed to present with the same prevalence of metastatic disease (3/5 and 2/3, respectively). All patients in the group without treatment died after in median 1 month following pathological diagnosis. One patient in the chemotherapy group was alive at 9-month follow up, and the others survived a median of 11 months. In the surgically treated group, 4/7 were alive at follow-up of a median of 154 months. Of the three deceased patients who had survived 44, 53 and 151 months, respectively, two had microscopically non-radical resection.
CONCLUSIONS: MCAC of the pancreas is, when locally confined and without metastases, associated with fairly good prognosis after surgical resection. In inoperable patients and for metastatic disease, outcome is poor.
(Less)
- author
- Björk Werner, Josefin LU ; Sturesson, Christian LU ; Dawiskiba, Sigmund LU and Andersson, Roland LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- in
- Annals of Gastroenterology
- volume
- 24
- issue
- 3
- pages
- 213 - 217
- publisher
- Hellenic Society of Gastroenterology
- external identifiers
-
- scopus:79961221866
- pmid:24713784
- ISSN
- 1108-7471
- language
- English
- LU publication?
- yes
- id
- 76f28e2d-4ed0-4d08-8829-037d887b0547
- alternative location
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959310/pdf/AnnGastroenterol-24-213.pdf
- date added to LUP
- 2021-06-11 13:51:09
- date last changed
- 2024-01-05 12:13:26
@article{76f28e2d-4ed0-4d08-8829-037d887b0547,
abstract = {{<p>BACKGROUND: Mucinous cystadenocarcinomas (MCAC) of the pancreas are rare tumors. When localized to the pancreas alone, surgical resection is mostly associated with a favorable prognosis. The potential value of palliative treatment with chemotherapy for irresectable disease is scarcely described though. The aim of this study was to describe a single-center series of patients with MCAC of the pancreas focusing on the outcome following different treatment strategies.</p><p>METHODS: 15 patients, 10 females and 5 males, with histologically or cytologically verified MCAC, were divided into three groups: surgical resection (n=7), chemotherapy (n=5) and no treatment (n=3).</p><p>RESULTS: There was no obvious difference in gender distribution between the subgroups. A tendency towards higher age was seen in the group without treatment, as was a larger tumor size as compared to the chemotherapy group. Patients were administered chemotherapy and the group without treatment seemed to present with the same prevalence of metastatic disease (3/5 and 2/3, respectively). All patients in the group without treatment died after in median 1 month following pathological diagnosis. One patient in the chemotherapy group was alive at 9-month follow up, and the others survived a median of 11 months. In the surgically treated group, 4/7 were alive at follow-up of a median of 154 months. Of the three deceased patients who had survived 44, 53 and 151 months, respectively, two had microscopically non-radical resection.</p><p>CONCLUSIONS: MCAC of the pancreas is, when locally confined and without metastases, associated with fairly good prognosis after surgical resection. In inoperable patients and for metastatic disease, outcome is poor.</p>}},
author = {{Björk Werner, Josefin and Sturesson, Christian and Dawiskiba, Sigmund and Andersson, Roland}},
issn = {{1108-7471}},
language = {{eng}},
number = {{3}},
pages = {{213--217}},
publisher = {{Hellenic Society of Gastroenterology}},
series = {{Annals of Gastroenterology}},
title = {{Mucinous cystadenocarcinoma of the pancreas - outcome following different modes of treatment}},
url = {{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959310/pdf/AnnGastroenterol-24-213.pdf}},
volume = {{24}},
year = {{2011}},
}